BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year

Reports revenue $1.4M vs. $1.9M last year. “Our first quarter results demonstrate continued momentum for CyPath Lung in the marketplace. As more and more physicians adopt CyPath Lung and share their experiences with peers, we see the opportunity to expand our commercial reach and bridge the diagnostic gap between imaging and invasive procedures, especially when dealing with indeterminate nodules in high-risk patients,” said Maria Zannes, CEO. “We are accelerating our marketing strategy to expand access to CyPath Lung and educate healthcare practitioners and patients alike about the need for accurate, objective information to better stratify risk and improve patient outcomes. On April 8, we hosted our first webinar featuring a panel of pulmonologists who shared how they use CyPath Lung in their diverse practices. Physicians continue to share their case studies in which CyPath Lung has identified lung cancer as early as Stage 1A when it is most treatable and conversely in which a negative CyPath Lung result helped avoid unnecessary invasive procedures. We believe the growing number of case studies and our longitudinal clinical trial, supported by leading military and VA institutions, will lead to broader adoption of CyPath Lung as part of the standard of care. We are uniquely positioned to fulfill the need for an accurate, noninvasive diagnostic for lung cancer, particularly when imaging and risk models are inconclusive or turn out to be wrong. The remainder of 2026 will be focused on scaling commercial execution, expanding into new geographic markets, and driving increased utilization of CyPath Lung through continued physician engagement while also leveraging our flow cytometry and AI platform to advance our pipeline of diagnostics for serious or life-threatening lung diseases.”